Janos Demeter

Janos Demeter

Auto-generated profile, based on publicly available information

Janos Demeter

Baxter Laboratory, Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, USA

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2003 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
TSTherese Sørlie
Therese Sørlie
RTRobert Tibshirani
Robert Tibshirani
JPJoel Parker
Joel Parker
THTrevor Hastie
Trevor Hastie
JMJ. S. Marron
J. S. Marron
DBDavid Botstein
David Botstein
Characteristic patterns of gene expression measured by DNA microarrays have been used to classify tumors into clinically relevant subgroups. In this study, we have refined the previously defined subtypes of breast tumors that could be distinguished by their distinct patterns of gene expression. A total of 115 malignant breast tumors were analyzed by hierarchical clustering based on patterns of expression of 534 “intrinsic” genes and shown to subdivide into one basal-like, one ERBB2 -overexpressing, two luminal-like, and one normal breast tissue-like subgroup. The genes used for classification were selected based on their similar expression levels between pairs of consecutive samples taken from the same tumor separated by 15 weeks of neoadjuvant treatment. Similar cluster analyses of two published, independent data sets representing different patient cohorts from different laboratories, uncovered some of the same breast cancer subtypes. In the one data set that included information on time to development of distant metastasis, subtypes were associated with significant differences in this clinical feature. By including a group of tumors from BRCA1 carriers in the analysis, we found that this genotype predisposes to the basal tumor subtype. Our results strongly support the idea that many of these breast tumor subtypes represent biologically distinct disease entities.

1 September 2020 in Cell
Verified
Journal Article
Open access
CSChristian Schuerch
Christian Schuerch
SBSalil S. Bhate
Salil S. Bhate
GBGraham L. Barlow
Graham L. Barlow
DPDarci J. Phillips
Darci J. Phillips
LNLuca Noti
Luca Noti
GNGarry P. Nolan
Garry P. Nolan
Antitumoral immunity requires organized, spatially nuanced interactions between components of the immune tumor microenvironment (iTME). Understanding this coordinated behavior in effective versus ineffective tumor control will advance immunotherapies. We re-engineered co-detection by indexing (CODEX) for paraffin-embedded tissue microarrays, enabling simultaneous profiling of 140 tissue regions from 35 advanced-stage colorectal cancer (CRC) patients with 56 protein markers. We identified nine conserved, distinct cellular neighborhoods (CNs)—a collection of components characteristic of the CRC iTME. Enrichment of PD-1+CD4+ T cells only within a granulocyte CN positively correlated with survival in a high-risk patient subset. Coupling of tumor and immune CNs, fragmentation of T cell and macrophage CNs, and disruption of inter-CN communication was associated with inferior outcomes. This study provides a framework for interrogating how complex biological processes, such as antitumoral immunity, occur through concerted actions of cells and spatial domains.

21 November 2019 in Cell
Verified
Journal Article
Closed access
KHKeren I. Hilgendorf
Keren I. Hilgendorf
CJCarl T. Johnson
Carl T. Johnson
AMAnja Mezger
Anja Mezger
SRSelena L. Rice
Selena L. Rice
ANAlessandra M. Norris
Alessandra M. Norris
PJPeter K. Jackson
Peter K. Jackson

18 November 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
DPDarci Phillips
Darci Phillips
MMMagdalena Matusiak
Magdalena Matusiak
BGBelén Rivero Gutierrez
Belén Rivero Gutierrez
SBSalil S. Bhate
Salil S. Bhate
GBGraham L. Barlow
Graham L. Barlow
GNGarry P. Nolan
Garry P. Nolan
Cutaneous T cell lymphomas (CTCL) are rare but aggressive cancers without effective treatments. While a subset of patients derive benefit from PD-1 blockade, there is a critically unmet need for predictive biomarkers of response. Herein, we perform CODEX multiplexed tissue imaging and RNA sequencing on 70 tumor regions from 14 advanced CTCL patients enrolled in a pembrolizumab clinical trial (NCT02243579). We find no differences in the frequencies of immune or tumor cells between responders and non-responders. Instead, we identify topographical differences between effector PD-1+ CD4+ T cells, tumor cells, and immunosuppressive Tregs, from which we derive a spatial biomarker, termed the SpatialScore, that correlates strongly with pembrolizumab response in CTCL. The SpatialScore coincides with differences in the functional immune state of the tumor microenvironment, T cell function, and tumor cell-specific chemokine recruitment and is validated using a simplified, clinically accessible tissue imaging platform. Collectively, these results provide a paradigm for investigating the spatial balance of effector and suppressive T cell activity and broadly leveraging this biomarker approach to inform the clinical use of immunotherapies.

24 January 2022 in Cell Stem Cell
Verified
Journal Article
Closed access
SMShamik Mascharak
Shamik Mascharak
HTHeather E. Talbott
Heather E. Talbott
MJMichael Januszyk
Michael Januszyk
MGMichelle Griffin
Michelle Griffin
KCKellen Chen
Kellen Chen
Michael T. LongakerMichael T. Longaker
Michael T. Longaker

1 March 2004 in Molecular Biology of the Cell
Verified
Journal Article
Open access
PDF file
MSMinoo Shakoury-Elizeh
Minoo Shakoury-Elizeh
JTJohn Tiedeman
John Tiedeman
JRJared Rashford
Jared Rashford
TFTracey Ferea
Tracey Ferea
JDJanos Demeter
Janos Demeter
CPCaroline C. Philpott
Caroline C. Philpott
Fungal APSES proteins regulate morphogenetic processes, including filamentation and differentiation. The human fungal pathogen Candida albicans contains two APSES proteins: the regulator Efg1p and its homologue Efh1p, described here. Overexpression of EFG1 or EFH1 led to similar phenotypes, including pseudohypha formation and opaque-white switching. An efh1 deletion generated no phenotype under most conditions but caused hyperfilamentation in an efg1 background under embedded or hypoxic conditions. This suggests cooperation of these APSES proteins in the suppression of an alternative morphogenetic signaling pathway. Genome-wide transcriptional profiling revealed that EFG1 and EFH1 regulate partially overlapping sets of genes associated with filament formation. Unexpectedly, Efg1p not only regulates genes involved in morphogenesis but also strongly influences the expression of metabolic genes, inducing glycolytic genes and repressing genes essential for oxidative metabolism. Using one- and two-hybrid assays, we further demonstrate that Efg1p is a repressor, whereas Efh1p is an activator of gene expression. Overall, the results suggest that Efh1p supports the regulatory functions of the primary regulator, Efg1p, and indicate a dual role for these APSES proteins in the regulation of fungal morphogenesis and metabolism.